Heart Valve Surgery: Repair and Replacement

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Cardiac Surgery".

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 1209

Special Issue Editors


E-Mail Website
Guest Editor
Division of Thoracic and Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA
Interests: transcatheter aortic valve implantation; heart valve prosthesis; aortic stenosis; mitral valve regurgitation; leaflet; tricuspid valve disease

E-Mail Website
Guest Editor
Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
Interests: transcatheter aortic valve implantation; heart valve prosthesis; aortic stenosis; mitral valve regurgitation; leaflet; tricuspid valve disease

Special Issue Information

Dear Colleagues,

In the current era, the management landscape for patients with valvular heart disease, particularly aortic stenosis, has undergone significant advancements, especially with the emergence of transcatheter interventions. Aortic stenosis is a prevalent valvular heart disease associated with significant morbidity and mortality, and management strategies have evolved to address the challenges posed by this condition. Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis, offering a less invasive alternative to surgical aortic valve replacement. This innovative approach has reshaped the landscape of aortic stenosis management, providing new opportunities for improving patient outcomes and the quality of life. Similar changes are occurring in the context of other valvular heart diseases, sparking patient selection, procedural refinements and long-term follow-up, and prompting a reevaluation of traditional treatment paradigms.

This Special Issue aims to explore and understand the evolving landscape of heart valve disease management in the current era, with a specific focus on the role of transcatheter interventions. By critically evaluating the impact of these advancements on patient care, we can enhance our understanding of the optimal management strategies and contribute to further refining the delivery of care for patients with heart valve disease. We invite researchers, clinicians and experts in the field to submit their work for consideration. The submissions presented in this Special Issue may include review articles, brief editorials, case reports or original research.

Dr. Sameer Hirji
Dr. Alexis Kofi Okoh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • aortic stenosis
  • mitral valve disease
  • tricuspid regurgitation
  • mitraclip
  • transcatheter aortic valve replacement

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1694 KiB  
Article
Safety and Efficacy in Mitral Regurgitation Management with the MitraClip® G4 System: Insights from a Single-Center Study
by Georgios E. Papadopoulos, Ilias Ninios, Sotirios Evangelou, Andreas Ioannidis and Vlasis Ninios
J. Cardiovasc. Dev. Dis. 2025, 12(1), 4; https://doi.org/10.3390/jcdd12010004 - 25 Dec 2024
Viewed by 866
Abstract
Background: Mitral regurgitation (MR) is a common valvular disorder linked to high morbidity and mortality. For patients unsuitable for surgery, transcatheter mitral edge-to-edge repair (TEER) with the MitraClip® G4 system offers an alternative. This study aims to evaluate procedural, echocardiographic, functional, and [...] Read more.
Background: Mitral regurgitation (MR) is a common valvular disorder linked to high morbidity and mortality. For patients unsuitable for surgery, transcatheter mitral edge-to-edge repair (TEER) with the MitraClip® G4 system offers an alternative. This study aims to evaluate procedural, echocardiographic, functional, and quality of life (QoL) outcomes in patients who underwent TEER with the MitraClip® G4 system, along with possible predictors of New York Heart Association (NYHA) class I at 30 days and at 1 year. Methods: Patients with moderate-to-severe (3+) or severe (4+) degenerative MR (DMR) or functional MR (FMR), classified as NYHA class III or IV, and who underwent TEER with the MitraClip® G4 system at our center between January 2021 and December 2023 were included. Results: A total of 83 patients [71% FMR, 66% male, median (IQR) age 70 (11) years] underwent TEER, with 100% procedural success. MR ≤ 2+ was achieved in 100% and 98% of patients at 30 days and 1 year, respectively. NYHA class I or II was achieved in 100% and 96.8% of patients at 30 days and 1 year, respectively. The Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved from 51 ± 20 at baseline to 69 ± 15 at 30 days (p < 0.001) and 70.5 ± 15 at 1 year (p < 0.001). Lower baseline N-terminal pro-brain natriuretic peptide (NT-proBNP) predicted achieving NYHA class I at 30 days (HR: 0.63, 95% CI: 0.41–0.95, p = 0.030), while lower European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and NT-proBNP predicted it at 1 year [(HR: 0.50, 95% CI: 0.28–0.89, p = 0.019), (HR: 0.67, 95% CI: 0.44–0.99, p = 0.049), respectively]. Conclusions: The MitraClip® G4 system provides significant improvements in MR severity, functional class, and QoL. Lower NT-proBNP and EuroSCORE II were strong predictors of achieving optimal functional status (NYHA class I). Full article
(This article belongs to the Special Issue Heart Valve Surgery: Repair and Replacement)
Show Figures

Figure 1

Back to TopTop